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Abstract
The immune system should constitute a strong selective pressure promoting viral genetic diversity and evolution. However,
HIV shows lower sequence variability at T-cell epitopes than elsewhere in the genome, in contrast with other human RNA
viruses. Here, we propose that epitope conservation is a consequence of the particular interactions established between HIV
and the immune system. On one hand, epitope recognition triggers an anti-HIV response mediated by cytotoxic T-
lymphocytes (CTLs), but on the other hand, activation of CD4+ helper T lymphocytes (TH cells) promotes HIV replication.
Mathematical modeling of these opposite selective forces revealed that selection at the intrapatient level can promote
either T-cell epitope conservation or escape. We predict greater conservation for epitopes contributing significantly to total
immune activation levels (immunodominance), and when TH cell infection is concomitant to epitope recognition (trans-
infection). We suggest that HIV-driven immune activation in the lymph nodes during the chronic stage of the disease may
offer a favorable scenario for epitope conservation. Our results also support the view that some pathogens draw benefits
from the immune response and suggest that vaccination strategies based on conserved TH epitopes may be
counterproductive.
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Introduction
Host cellular immunity is thought to be a major factor
determining the evolution of HIV-1 and other human viruses,
from the intrapatient to the global population level [1,2]. It has
been shown that cytotoxic CD8+ T lymphocytes (CTLs) and
helper CD4+ T lymphocytes (TH cells) play a critical role in the
early and long-term containment of the virus [3–10]. Further-
more, there is epidemiological evidence showing that certain HLA
class I alleles (e.g., B27 andB57) influence the rate of disease
progression [11–14], and HLA-associated HIV-1 polymorphisms
may contribute significantly to the global viral diversity and
evolution [1,15–19]. Given this, HIV-1 genome regions encoding
T-cell epitopes should be under frequent positive or diversifying
selection, and thus, these regions should show increased genetic
variability. However, unexpectedly, the opposite pattern has been
observed in several studies [4,20–27].
The reasons underlying the relatively low genetic diversity of T-
cell epitopes in HIV-1 remain poorly understood. One proposed
explanation is epitope detection bias [23,28], whereby mismatches
between the peptides used in epitope screening studies and the
actual sequence of the assayed viruses tend to produce false
negative results in highly variable regions of the viral genome,
creating an artificial negative association between immunogenicity
and variability. It has also been suggested that epitope conserva-
tion may be determined by host factors. The immuno-proteasome
preferentially processes hydrophobic residues, and these should
tend to show relatively low variability because they often occupy
internal regions of the protein that are important for correct
folding [29,30]. Finally, it has been suggested that regions of the
viral genome where functional constraint is weaker may have
evolved generalized immune escape at the global host population
level and thus show fewer extant epitopes than other, more
constrained regions [23,31]. However, analysis of HIV-1 sequenc-
es spanning several decades was not consistent with this hypothesis
[32], and there is little phylogenetic evidence supporting global
escape in HIV-1 [33]. Furthermore, all the above hypotheses fail
to explain why no systematic T-cell epitope conservation has been
observed in other highly variable and prevalent human viruses
such as influenza, hepatitis C, and dengue viruses [34–37].
Here, we first carried out a sequence variability analysis to
validate and further characterize epitope conservation in HIV-1.
Confirming previous findings, sites in the viral genome mapping to
both TH and CTL epitopes were consistently less variable than
those not mapping to any described T-cell epitopes. In contrast,
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T-cell epitopes tended to be associated with increased variability
levels when this same analysis was carried out for hepatitis C virus
(HCV). We also found that HIV-1 epitope conservation was
probably determined by intrapatient evolutionary processes and
was evident in Gag p24 and Nef proteins even after accounting for
epitope detection bias. Based on this, we hypothesized that T-cell
epitope conservation may result from the particular interactions
established between HIV-1 and the immune system. Although
epitope recognition triggers an anti-HIV immune response, the
virus replicates more efficiently in activated TH cells [38–46].
Therefore, the variability of T-cell epitopes may be determined by
the balance between two opposite selective pressures, one favoring
immune escape and another favoring immune activation. To
tackle this issue, we developed a mathematical model of the
intrahost infection dynamics and T-cell responses. We found that
sequence conservation may be favored at TH epitopes or CTL
epitopes co-mapping with TH epitopes, whereas immune escape
should be selected otherwise. The model suggested that epitopes
triggering vigorous (immunodominant) TH -cell responses should
be more conserved than those triggering weak or moderate
responses. This is consistent with the fact that epitope conservation
was better supported for highly immunogenic proteins such as Gag
p24 and Nef [10,20]. Furthermore, we predict that epitope
conservation may be favored if TH cells frequently become
infected in the process of being activated by professional antigen-
presenting cells (pAPCs) (transinfection). Since transinfection
appears to be an important mechanism for viral dissemination in
the lymph nodes during the chronic stage of the disease [47–49],
our model may help to explain why escape rates tend to slow down
as the infection progresses [50–52]. Finally, our findings suggest
that vaccines that do not elicit HIV-specific TH cell activation may
have improved efficacy.
Empirical Evidence for Epitope Conservation in HIV-1
To confirm widespread T-cell epitope conservation in HIV-1,
we downloaded 100 full-length subtype B sequences from different
patients and 220 experimentally validated epitopes (CTL or TH)
from the Los Alamos HIV-1 database. The epitope list included
the ‘‘A list’’ of 88 best-defined epitopes CTL epitopes and also 132
TH epitopes. Using Shannon’s entropy (H) to quantify variability
at each amino acid site, we found that sites mapping to T-cell
epitopes tended to be more conserved than those not mapping to
any of these epitopes (Figure 1A). This association appeared to be
mainly driven by CTL epitopes in Env (two-way ANOVA:
p,0.001) and Nef (p,0.001) proteins, and by TH epitopes in Gag
(p = 0.005). However, the separate effects of TH and CTL epitopes
are difficult to ascertain because they tend to co-map in the HIV
genome (Fisher’s exact test: p,0.001) [53] and, also, because
epitopes currently classified as CTL-only may actually be TH
epitopes as well, since the latter group has been less extensively
studied. The most consistent conservation pattern was observed
when comparing sites that mapped to both CTL and TH epitopes
(H = 0.14660.016) with those not mapping to any of these
epitopes (H = 0.25560.01; nested ANOVA: p,0.001).
To check that the results were not dependent on how epitopes
have been curated, we repeated the analysis using the complete list
of 741 CTL epitopes instead of the ‘‘A list.’’ This confirmed T-cell
epitope conservation throughout the genome (nested ANOVA:
p,0.001). Although the above analyses accounted for differences
in variability across genes, we further checked whether epitope
conservation may be a by-product of other selective factors in two
ways. First, we included RNA structure in the analysis, a major
factor constraining HIV variability [27,54]. We found that
nucleotide sites mapping to T-cell epitopes were more conserved
than those not mapping to these epitopes regardless of whether
they were involved in establishing base-pairs in the genomic RNA
structure of the virus (nested ANOVA: p,0.001). Second, we
verified that epitope conservation was not a byproduct of 59R39
variability gradients by introducing genome position as a covariate
in the analysis.
To assess whether epitope conservation is determined by
intrapatient or host population-level evolutionary processes, we
downloaded $10 HIV-1 subtype B sequences from each of 100
patients and calculated the average intrapatient amino acid
entropy at each amino acid site. Since HIV transmission typically
involves one or a few viral particles [55–57], the intrapatient
sequence entropy largely reflects the variability accumulated over
the course of an individual infection. We again observed that sites
mapping to T-cell epitopes (CTL ‘‘A list’’ and TH) tended to be
more conserved (H = 0.01260.001) than those not mapping to any
of these epitopes (H = 0.01860.001; nested ANOVA: p,0.001;
Figure 1B). Indeed, changes in entropy associated with the
presence of T-cell epitopes were qualitatively very similar to those
observed at the host population level (Figure 1A versus 1B). This
suggests that T-cell epitope conservation in HIV-1 is determined
at the intra-patient level.
If T-cell epitope conservation was a methodological artifact
(e.g., epitope detection bias) or produced by host factors (e.g.,
selective peptide processing), it should also be evident in other
highly variable human viruses. HCV provides a convenient test
case because, similar to HIV, it is a rapidly evolving pandemic
virus, establishes chronic infections in humans, and is strongly
targeted by T-cell immunity [58–63]. We aligned 100 HCV
subtype 1a polyprotein sequences, calculated the per-site amino
acid entropy as above, and downloaded experimentally defined
HCV 1a TH or CTL epitopes from the Immune Epitope Database
(IEDB). We found that, throughout the genome, amino acid sites
mapping to at least one T-cell epitope were significantly more
variable (H = 0.73060.007) than those not mapping to any of
these epitopes (H = 0.63660.004; nested ANOVA: p,0.001), the
Author Summary
A key component of the immune response against viruses
and other pathogens is the recognition of short foreign
protein sequences called epitopes. However, viruses can
escape the immune system by mutating, so epitopes
should accumulate high levels of genetic variability. This
has been documented in several human viruses, but in
HIV, unexpectedly, epitopes tend to be relatively con-
served. Here, we propose that this is a consequence of the
peculiar interactions that occur between HIV and the
immune system. As with other viruses, recognition of HIV
epitopes promotes the activation of cytotoxic and helper T
lymphocytes, which then orchestrate a cellular immune
response. However, HIV infects helper T lymphocytes as
their target cell in the body and does so more efficiently
when these cells have been activated to participate in an
immune response. Mathematical modeling showed that, in
some cases, HIV may take advantage of immune activa-
tion, thus favoring epitope conservation. This should be
more likely to occur with epitopes that trigger more
vigorous T-cell responses, and during the process known
as ‘‘trans-infection,’’ in which helper T lymphocytes are
infected while being activated. Our results highlight the
potential advantages of an HIV vaccination strategy based
on epitopes that stimulate cytotoxic T lymphocytes
without specifically stimulating helper T lymphocytes.
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association being most evident for genes E2 and NS4b (Figure 1C).
This pattern contrasts with the results obtained for HIV.
To further characterize T-cell epitope conservation in HIV, we
used a dataset from a high-throughput study in which T-cell
responses were determined for a large number of individuals
infected with HIV-1 subtype C using the IFNc enzyme-linked
immunospot assay [18]. Thus, epitopes were empirically verified
for each patient. These assays involved a battery of synthetic
peptides evenly distributed throughout the viral genome, thus
eliminating potential problems of region oversampling. Further-
more, the full genome sequence of the infecting virus was available
for 113 patients, allowing us to identify every mismatch between
the assay peptides and the viral sequence and, thus, to
systematically discard epitope detection bias. Among these 113
patients, peptides showing at least one positive immune response
were less variable (H = 0.16560.014) than nonimmunogenic
peptides (H = 0.21060.008; one-way ANOVA: p = 0.005), thus
confirming epitope conservation. This difference was significant
for Gag p24 (one-way ANOVA: p = 0.001) and Nef (one-way
ANOVA: p,0.001), whereas it was nonsignificant for Gag p17,
Pol, and Env (Figure 2). Qualitatively equivalent results were
obtained using the number of amino acid substitutions per codon
(dN) instead of entropy, whereas we found no association between
immunogenicity and the number of synonymous substitutions (dS)
(Table 1). The latter lack of association further shows that epitope
conservation is unlikely to stem from selective pressures acting on
RNA structure or from 59R39 conservation gradients. Consis-
tently, nonimmunogenic peptides were richer in positively selected
codons (dN/dS.1) than immunogenic peptides in both Gag p24
and Nef. Finally, we note that these results are probably more
reliable for Gag p24 than for Nef since they are based on a larger
number of assays (1,485 versus 357).
The Immune Activation Model
We sought to develop a model that could account for the
following observations made above: T-cell epitopes are less variable
than other regions of the viral genome; epitope conservation
appears to be determined by intrapatient evolutionary processes;
after ruling out possible confounders, the conservation signal is
found mainly in highly immunogenic proteins; HCV and other
human viruses do not show widespread epitope conservation. Also,
since both T-cell escape and epitope conservation have been
documented in HIV-1, it becomes important to identify key factors
determining which of these outcomes should take place.
We suggest that, since HIV-1 replicates more efficiently in
activated TH cells, epitope conservation may provide payoffs to the
virus by increasing the pool of virus-susceptible cells. On the other
hand, epitope conservation is costly because it triggers an anti-
HIV CTL response. To explore how the complex interactions
established between HIV-1 and the cellular immune system may
favor or select against epitope escape, we built a mathematical
model involving TH cells, CTLs, and pAPCs (Figure 3A). We
included pAPCs because TH cell activation is mediated by MHC
II epitopes, which are only present in pAPCs. Also, pAPCs are an
important viral transmission vehicle (see below). In the model, TH
cells could be activated by HIV epitopes or other, non-HIV,
antigens (e.g., from microbial translocation). We denoted the latter
background activation. Dendritic cells are the main type of pAPCs
in the context of an HIV infection, but macrophages also fall into
this category. CTL activation required recognition of an HIV
epitope presented by the MHC I of an infected TH cell or a pAPC,
and co-stimulatory cytokines released from active TH cells.
Cytokine co-stimulation was not epitope-specific, meaning that it
could also come from background-activated TH cells. Background
activation of CTLs is not relevant in the context of the model and
was thus not considered. Activated CTLs lysed infected TH cells
after recognizing an MHC I epitope. However, error-prone
replication gave rise to progeny virions carrying escape mutations
in their CTL or TH epitopes. We defined CTL escape mutants as
those failing to trigger MHC I-mediated CTL activation and cell
killing, TH escape mutants as those failing to trigger MHC II-
mediated TH cell activation, and T-cell escape mutants as those
escaping both types of response.
Critically, HIV-1 replication and viral load are dependent on
levels of TH cell activation [38–41]. In nonactivated cells, the
efficiency of reverse transcription is lower than in activated cells
because of the limited dideoxynucleotide availability , low ATP
levels hamper nuclear transport of the pre-integration complex,
and gene expression is less well-supported by key transcription
factors such as NF-kB and NFAT [42–44]. As a result, the
infection cycle can be arrested at the reverse transcription step and
the incomplete viral DNA degraded unless the cell undergoes
activation within days following viral entry [42,45,46]. TH cells
can become infected in the process of being activated by pAPCs,
though. A mechanism for this is transinfection, whereby dendritic
Figure 1. Association between amino acid variability and T-cell epitopes in subtype B HIV-1 (A, B) and HCV 1a (C). Mean 6 SEM
entropy (H) is shown for sites not mapping to any T-cell epitopes (white) and for those mapping to TH epitopes (blue), CTL epitopes (red), or both
(purple). In (A) and (C) amino acid entropy was quantified at the host population level (100 sequences from different patients), whereas in (B) it was
quantified at the intrapatient level (average from 100 patients containing $10 sequences each). For HIV, only Gag, Pol, Env, and Nef are shown
because they contain the vast majority of T-cell epitopes. No significant differences in variability associated with T-cell epitopes were found in other
genes. Regions with overlapping reading frames were excluded from the analysis. For HCV, only genes with at least five sites in each category were
plotted. Notice that the y-axis is broken to accommodate the extremely variable epitopes in E2.
doi:10.1371/journal.pbio.1001523.g001
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cells can transmit virions bound to their DC-SIGN or L-SIGN
lectins to the TH cells with which they establish MHC II-type
immune synapses [48,49]. Another possible mechanism is cis-
infection, whereby virions released from infected dendritic cells or
macrophages are transmitted to synapsing TH cells. However,
pAPCs are not major viral producers [64], and therefore, we
neglected viral replication in these cells and cis-infection for
simplicity. The contribution of HIV-specific immune activation
and transinfection to viral spread and pathogenesis is supported by
the observation that HIV-specific TH cells are more readily
infected than other subpopulations of active TH cells [65],
reducing their life span and compromising the generation of
effective anti-HIV responses [66].
We also built a ‘‘control’’ model in which the virus infects
nonimmune cells (denoted C) instead of TH cells, but which was
otherwise identical to the HIV model (Figure 3B). This allowed us
to parallel the comparison between HIV and HCV made above
(Figure 1). To address whether TH and CTL escape mutants
should be capable of outgrowing the wild-type virus given the
intrapatient selective forces imposed by the cellular immune
response in the HIV and control models, we considered a single
immune response-escape cycle. Successive cycles ultimately
leading to immune exhaustion and AIDS have been modeled
previously and are important for understanding the natural history
of the infection and pathogenesis [67–69].
Some of the model parameter values could be adjusted based on
available empirical evidence. We chose a cell division rate (r) of
0.05 day21 (i.e., a doubling time of 13.9 days) and a death rate (C)
of 0.005 day21 for resting cells (a half-life of t1/2 = 139 days) and of
0.1 day21 (t1/2 = 6.9 days) for activated cells [70]. The homeostatic
TH cells concentration was C
0
4 r½ 
~1,000 cells=mL [71]. We
assumed that cellular division was suppressed above the homeo-
static value, and this was modeled using a unit step function
Figure 2. Association between amino acid variability and T-cell immunogenicity in HIV-1 subtype C using data from a high-
throughput study [18], controlling for epitope detection bias (see text). The average entropy (H) is shown for peptides that produced at
least one positive immune reaction (red) versus those showing no reactivity (blue). Only genes with at least five peptides in each category are shown.
Genome regions with overlapping reading frames were excluded. Dotted lines indicate ANOVA-estimated marginal means. ** 0.001,p,0.01;
*** p,0.001. n.s., not significant.
doi:10.1371/journal.pbio.1001523.g002
Table 1. Estimated number of nonsynonymous substitutions
per codon (dN), synonymous substitutions per codon (dS), and
percentage of codons under positive selection (% dN.dS) in
peptides showing at least one positive immune reaction
(epitopes) versus those showing no reactions (non-epitopes),
using data from a HIV-1 subtype C high-throughput study
[18].
Protein Epitopes Nonepitopes
dN dS % dN.dS dN dS % dN.dS
Gag p17 2.860.3 4.460.2* 6.562.4 2.860.4 5.460.3* 6.263.7
Gag p24 0.860.1** 3.960.3 1.460.9** 1.560.1** 4.260.3 5.861.0**
Pol RT 1.160.1 4.960.3 1.861.1 1.260.1 4.660.1 3.360.5
Pol INT 0.860.1 3.860.5 2.161.4 0.860.1 3.860.3 2.260.7
Env 2.361.3 4.561.0 11.363.6 3.760.4 5.660.3 10.361.0
Nef 1.960.2** 5.160.4 2.861.2* 3.160.2** 5.960.4 7.361.5*
Total 1.760.2* 4.760.2 4.460.8* 2.260.1* 5.060.1 6.260.4*
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(denoted H). The death rate constant of infected cells was C4 i½  = 1
day21 [72–77], and the viral production rate of infected cells (a)
was chosen such that the burst size was a/C4 i½  = 5,000 particles/
cell, a value which falls within the realistic range of 16103–56104
particles/cell [78–81]. The rate constant for CTL-mediated cell
killing was k = 0.1 day21 = C4 i½ /10, such that at equilibrium
approximately 10% of virus-induced cell death was due to CTL
activity [52]. Published virion clearance constants (CV) vary amply,
from 0.3 day21 [72,76] to .30 day21 [82], and we chose an
intermediate value of 15 day21. The HIV-1 mutation rate is
approximately m = 361025 per nucleotide site per cell infection
[83]. To consider a single escape mutant, we set the mutation rate
to m = 1025. For some parameters, such as the in vivo rate of viral
absorption to TH cells (s) and pAPCs (sD), we did not find
empirical data and these were adjusted to produce realistic peak
titers, set-point titers, and fractions of infected cells. Virus–cell and
cell–cell interactions were modeled as AB/(A+B), where A and B
are the interacting elements. For instance, TH cells infected with
the wild-type virus (TH w½  ) were killed by activated CTLs (TC a½  ) at
a rate k
TC a½ TH w½ 
TC a½ zTH w½ 
. In this function, cell killing is limited by target
cell availability if TC a½ &TH w½  and by CTL availability if
TC a½ %TH w½  . Thus, cell infection and activation were modeled as
saturating processes. We assumed that infection rates for each viral
type saturate as a function of the total viral density. For instance,




, where V48 is the load of T-cell escape




. Thus, wild-type infection rates decreased as
the density of escape viruses increased and vice versa, reflecting
competition among viruses for cells. The full list of variables and
parameters and the systems of ordinary differential equations
defining the models are shown in the Appendix S1.
We started simulations with one infected cell and homeostatic
values of resting target cells (TH or C). We also provided a large pool
of HIV-susceptible active TH cells for the primary infection to
mimic the initial spread of HIV through the mucosa or gut-
associated lymphoid tissue (GALT). The model captured the typical
HIV infection dynamics, in which viral load increases rapidly until
reaching a peak days or weeks after transmission and subsequent
exhaustion of the initial pool of susceptible cells and CTL activation
make the viral load drop but fail to eradicate the infection (Figure 4).
A dynamic equilibrium or set point was reached in which the virus
continued to replicate, the immune system remained activated, and
viral loads showed stable values within the typical range of 103 to
105 viral copies/mL [84] for the parameter values used. The control
model produced similar dynamics.
CTL (non-TH) escape mutants always became dominant in both
the HIV and control models, whereas TH (non-CTL) cell escape
mutants were neutral in the control model and neutral or
Figure 3. Schematic representation of the HIV immune activation model and the control model. (A) Model of the cellular immune
response against HIV. In the absence of immune activation, pools of resting TH (CD4) cells, CTLs (CD8), and pAPCs divide at rates, r4, r8, rD and die at
rates C4 r½  , C8 r½  , and CD r½  , reaching homeostatic concentrations C
0
4½r
, C08½r , and C
0
D½r, respectively. Activated TH cells become infected through contact
with free virions at a rate constant s, whereas resting cells are assumed to be non-susceptible to the virus. TH cells are activated at a rate constant a4
after contacting a pAPC with an HIV epitope or by other antigens at rate constant b (background activation). TH cells establishing synapses with
pAPCs have a probability d of being concomitantly infected with the same viral type. Infected cells release virions at a rate constant a and die at a rate
constant C4½i. CTL pre-activation occurs after contacting infected cells (a8) or pAPCs (a8D). A co-stimulatory signal from activated TH cells is necessary
for completing CTL activation (a89). Infected cells are lysed by CTLs at a rate constant k. Death rate constants for activated TH cells (C4½a ), CTLs (C8 a½  ),
and pAPCs (CD a½  ) and virion inactivation rates (CV) are not shown for simplicity. The full list of variables and parameters is available in Appendix S1,
which also provides references to empirical work justifying the parameter values used (see also main text). A fraction m of the virions released in each
cell infection become escape mutants. Avoidance of CTL activation or CTL-mediated killing leads to CTL escape (red bars), whereas avoidance of TH
cell activation leads to TH escape (blue bars). The model allows full T-cell (purple), TH-only (blue), and CTL-only (red) escape mutants. (B) Control
model in which the virus targets a nonimmune cell type C (e.g., hepatocytes, epithelial cells, etc.) instead of TH cells. Two key differences with the HIV
model are that viral replication is not dependent upon immune activation and that transinfection does not take place. Variables, parameters, and
equations for this model are also shown in Appendix S1.
doi:10.1371/journal.pbio.1001523.g003
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deleterious in the HIV model (not shown). The reason why TH cell
escape does not per se provide a fitness advantage is that these
mutants can be targeted by CTLs activated by the wild-type virus
or other antigens. In addition, in the HIV case, TH escape mutants
act as a sink of susceptible cells and are thus dependent on cells
activated by the wild-type virus or on background activation for
replicating, making them potentially deleterious. Therefore,
considering CTLs and TH cells together, full T-cell (TH and
CTL) escape may be favored or selected against depending on the
balance between the benefits of CTL escape and the potential
costs of TH escape. We are able to find parameter values that
produced T-cell escape rates similar to those reported in studies of
patient serial samples (Figure 4) [50,67]. The timing of escape
could also be varied from weeks postinoculation to years. In
contrast, other parameter combinations disfavored T-cell escape
mutants, and epitopes remained invariant if the infection was
initiated with the wild-type, or they reverted to the wild-type if the
infection was initiated with escape mutants (Figure 4C, F). In these
cases, epitope conservation was promoted. In contrast, in the
control model, T-cell escape occurred systematically and the rate
of escape was faster than in the HIV case for the same parameter
values. This showed that epitope conservation can be explained by
the particular nature of the HIV infection, in which TH escape can
be costly for the virus.
A central goal of our HIV model was to identify factors
determining whether T-cell escape or epitope conservation should
take place. We found that transinfection probability and immune
activation levels were two such factors (Figure 5). Since
transinfection implies a temporal and spatial association between
TH cell activation and infection, there should be some correlation
between the type of epitope (wild-type or escape mutant) presented
by a pAPC and the type of virion transmitted to synapsing TH
cells. We denoted this correlation d. In the absence of transinfec-
tion or if every pAPC contained equal amounts of wild-type and
T-cell escape virions, then d = 0, and therefore, TH cells activated
by the wild-type virus would be fully accessible to T-cell escape
viruses. As a result, TH escape should not be detrimental to the
virus, and considering the benefit of evading CTLs, the net effect
of T-cell escape should be positive. In the control model, since
there was no possible transinfection, T-cell escape was always
advantageous. In the HIV model, in contrast, as d increased, T-cell
escape mutants had less and less access to TH cells activated by the
wild-type virus, and since they could not produce their own pools
of activated TH cells, these mutants had a selective fitness
disadvantage and failed to outgrow the wild-type virus. The
magnitude of this disadvantage depended inversely on levels of
background activation, because the latter is a source of susceptible
cells equally accessible to the wild-type and the escape mutant.
Also, for d.0, the outcome depended on the strength of epitope-
specific immune activation relative to background activation. If the
epitope failed to produce T-cell activation (anergy), there was
obviously no advantage associated with escape. Simulations also
showed, however, that if the epitope triggered a strong T-cell
activation (immunodominance), the escape mutant was disfavored
too because the pool of activated TH cells to which the escape
mutant had limited access represented a large portion of total
susceptible cells. Therefore, the model suggests that, in HIV,
immune escape should preferentially take place among epitopes
triggering weak to moderate T-cell responses.
Conclusions
If immune avoidance is beneficial for a virus, escape mutants
should tend to accumulate throughout the course of the infection
unless they incur fitness costs (i.e., defects in other steps of the
Figure 4. Simulated viral load versus time for combinations of parameter values producing biologically meaningful peak loads,
viral loads at set point (copies/mL), and escape rates (days21). In top panels, wild-type and T-cell (CTL/TH) escape variants are shown in black
and purple, respectively. Solid lines refer to the HIV model, whereas dashed lines correspond to the control model. HIV-specific activation rate
constants (a4, a8, a8D, a89), the background activation rate constant (b), and transinfection probability (d) were as indicated below, whereas all other
parameters values were set as indicated in the text. (A) a4 = a8 = a8D = a89 = 0.1, b = 0.001, d = 0.03; (B) a4 = a8 = a8D = a89 = 0.1, b = 0.001, and d = 0.037;
(C) a4 = a8 = a8D = a89 = 0.15, b = 0.001, d = 0.03, and the infection was started with a T-cell escape mutant. (D, E, and F) Changes in the intrapatient
frequency of the escape mutant for the HIV (solid) and control (dashed) models obtained in (A), (B), and (C), respectively. (D) The calculated rate of
escape, as defined in previous work [50], was 0.012 day21 in the HIV model and 0.091 day21 in the control model. (E) The escape mutant reached a
stationary frequency of 0.324 in the HIV model and became fixed in the control model (fixation rate: 0.091 day21). (F) The escape mutant was selected
against and reverted to the wild-type in the HIV case (reversion rate: 0.012 day21), whereas it remained fixed in the control model.
doi:10.1371/journal.pbio.1001523.g004
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infection cycle not related to immune evasion) exceeding the
benefits of escape. According to this, fast mutating viruses eliciting
strong T-cell responses and establishing chronic infections should
show the highest frequencies and rates of escape. Upon
transmission to new hosts with different HLA types, however,
the selective advantage of these mutants disappears and the virus
should tend to revert to the wild-type if the escape mutation has
some fitness cost, as has been amply documented in HIV [85–91].
This indeed constitutes a particular instance of antagonistic
pleiotropy, a frequent process among RNA viruses whereby
selectively advantageous mutations in one environment become
deleterious in other environments [92]. As a result of this
alternating selective regime, viral sequence variability at the
population level should be promoted and epitopes should tend to
be more variable than other genome regions. Previous work and
our sequence data analysis (Figure 1) show that HCV fits well into
this pattern, whereas HIV-1 does not.
The immune activation model provides a possible explanation
for the unexpected epitope conservation in HIV-1. The model
predicts that T-cell escape can be selected against depending on
factors such as transinfection probability, immune activation
levels, or epitope strength. Although CTL escape should per se
be advantageous for the virus, CTL epitopes may be conserved if
they co-map with TH epitopes. As shown here and in previous
work [53], CTL/TH epitope co-mapping occurs more often than
expected by chance, probably because these two types of epitopes
share common cellular pathways. Depending on the above factors,
thus, T-cell escape may occur only in some genome regions or
only in certain individuals. In this sense, the model contributes to
resolving the apparent paradox between T-cell epitope conserva-
tion and the large body of evidence showing that T-cell immunity
is an important selective factor promoting HIV variability. These
disparate findings are unlikely to result from use of different
datasets or methodologies. For instance, in one study, it was found
that that there was a general positive association between specific
HLA types and the occurrence of escape mutations, but that this
association was negative in some cases (i.e., epitopes were
significantly more conserved among patients with the relevant
HLA type than among those with nonmatching HLAs) [93]. It is
also noteworthy that some escape mutations are rapidly favored,
whereas others become dominant only after years of intrahost
replication [52,94]. This is often interpreted in terms of the fitness
costs of escape mutations [51,67,88–90]. However, the immune
activation model can also account for variable rates of escape even
in the absence of fitness costs. Indeed, our model did not assume
any fitness costs for escape mutations. Such costs may explain why
some escape mutations increase in frequency more slowly than
others, fail to be selected, or do not spread in the host population
[26]. However, they cannot explain why genome regions
containing T-cell epitopes tend to be more conserved than those
not containing epitopes, since costs should equally apply to both.
The combination of parameters for which we predicted T-cell
epitope conservation should be more likely in the lymph nodes at
the chronic stage of the disease, during which HIV-specific
activation of TH cells contributes to sustaining the infection and
pAPC-mediated coupled activation-infection of TH cells should be
frequent [47–49]. In contrast, the GALT and other mucosa
contain large pools of background-activated and recent memory
TH cells which are exploited by HIV during primary infection,
thus making the virus less dependent on its own ability to activate
TH cells [95–97]. It has been previously shown that T-cell escape
rates are higher during primary infection than in the chronic stage
of the disease [50–52]. Again, this is often interpreted in terms of
fitness costs, since escape mutations paying weak fitness costs
should be selected faster and be detected at earlier disease stages
than those paying strong costs. Another interpretation is that
epitopes triggering more vigorous T-cell responses tend to
experience faster escape due to the stronger selective pressure
exerted. Our model offers yet another possible interpretation: T-
cell escape may actually be slowed down whenever HIV depends
on its own ability to activate TH cells for replicating, and this is
more likely to occur during the chronic stage than during primary
infection. If the timing of escape was determined by fitness costs,
then late escapes should tend to revert faster than early escapes
upon transmission to new individuals with different HLA types
because of their greater deleteriousness, whereas if the timing of
escape was determined by immune activation levels, the reverse
should be true. These predictions offer a way of testing the above
alternative explanations for why rates of escape differ during the
primary and chronic stages of the disease. Sequence analysis
revealed that, after accounting for dataset biases, epitope
conservation occurred mainly in Gag p24 and Nef (Figure 2). As
expected from the immune activation hypothesis, these proteins
contain several immunodominant epitopes [20,98], whereas they
are not necessarily more likely to exhibit fitness costs than other
HIV genes.
Finally, our model suggests that vaccines based on conserved
TH epitopes might be counterproductive. By creating a pool of
HIV-responsive TH cells, they may pave the way for viral
replication in certain body compartments. This might contribute
to understanding the unexpected results of the STEP vaccine trial,
in which the vaccinated group was found to be at higher risk of
infection than the placebo-treated control group, although there
are many other possible explanations [99,100]. According to our
model, an efficient approach to HIV vaccination may be to use
CTL epitopes that do not stimulate TH cells. These epitopes may
be combined with non-HIV TH epitopes that would co-stimulate
CTLs without providing the immune system with a pool of HIV-
specific memory TH cells. The idea that immune activation can
Figure 5. Immune escape dependence on the HIV-driven T-cell
activation rate constant (a4), trans-infection probability (d),
and background activation (b). Shaded areas indicate parameter
combinations for which T-cell escape mutants became dominant
(frequency .0.5) after t = 1000 iterations (days). T-cell activation rate
constants were set equal to one another (a8 = a8D = a89 = a4), and the
rest of parameter values were as indicated in the text.
doi:10.1371/journal.pbio.1001523.g005
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favor pathogen replication and that, consequently, vaccines based on
conserved epitopes may be counterproductive has also been
proposed for Mycobacterium tuberculosis [101], although the mecha-
nisms at play have not been elucidated in this case and may
potentially differ from those of HIV. Interestingly, tuberculosis-
specific TH cells are also preferentially depleted in HIV-infected
individuals, whereas this is not observed in cytomegalovirus, another
opportunistic pathogen [102,103]. It is possible that, by triggering
immune activation, M. tuberculosis may benefit from HIV-mediated
depletion of TH cells and subsequent immune impairment.
Methods
Sequence Analysis
A BLAST of the entire reference subtype B sequence (HXB2)
was performed using the HIV Sequence Database search tool
(www.hiv.lanl.gov/components/sequence/HIV/search/search.html),
restrictfing the search to one sequence per patient. For each Gag,
Pol, Env, Vif, Vpu, Vpr, and Nef, 100 translated sequences were
aligned using the MUSCLE algorithm implemented in MEGA v5
(megasoftware.net) and HXB2 as reference sequence. Sequences
with premature stop codons or partial readings were removed.
Protein Shannon’s entropy was calculated for each site of the
alignment as S~
P
pln pð Þ, where p denotes the frequency of each
of the amino acids present at this site. Gaps were treated as another
amino acid. These calculations were carried out using Entropy-one
tool of the HIV Sequence Database with default options. To
estimate synonymous (dS) and nonsynonymous (dN) substitutions
rates from nucleotide sequences, we first used the Datamonkey
server (www.datamonkey.org) to select the best substitution model
and to identify significant recombination breakpoints using the
GARD algorithm [104], using default parameters except for the
inferred substitution model. Using this output, we run the SLAC
algorithm [105] implemented in the HYPHY package [106] to
identify codons under significantly positive or negative selection at a
0.1 probability threshold, and to estimate dN and dS. For the
intrapatient entropy analysis, HIV-1 subtype B sequences were
downloaded for each Gag, Pol, Env, and Nef from the HIV
Sequence Database using the intrapatient search tool and restricting
the search to patients with at least 10 sequences available and with
known time since infection/seroconversion or Fiebig stage. Entropy
values were obtained as above and, for each amino acid site, the
within-host entropy was averaged over 100 patients. For HCV, 100
full-length subtype 1a genomes were downloaded from GenBank
and translated to polyprotein sequences. Alignments and subse-
quent analyses were done as above, using the H77 sequence as
reference.
Epitope Mapping and Analysis
HIV CTL and TH epitopes were downloaded from the HIV
Molecular Immunology Database (www.hiv.lanl.gov/content/
immunology/tables/tables.html). For CTL epitopes, we used the
full set of 741 entries or a curated list of 88 best defined epitopes
(‘‘A list’’), whereas for TH epitopes we used the 132 available
entries (no curated list has been defined for this group). Each
epitope was aligned to the HXB2 sequence, and HXB2 genome
sites were classified based on whether they mapped to at least one
epitope. HCV subtype 1a epitopes were downloaded from the
IEDB (www.immuneepitope.org) selecting the specific epitope type
(MHC I for CTL epitopes and MHC II for TH epitopes), peptides
from proteins as structure type, and Homo sapiens as host organism.
This yielded 101 CTL and 27 TH epitopes. Genome-wide
differences in amino acid entropy associated with the presence
of T-cell epitopes were tested using a fixed-factor nested ANOVA
(presence/absence of T-cell epitope nested within gene). For HIV,
the contribution of RNA structure to the observed variability was
tested using nucleotide instead of amino acid sites and adding this
factor to the above ANOVA design (paired/nonpaired site
according to published structure, nested within gene). The effect
of 59R39 gradients was tested by including genome position as a
covariate in the model. Separate effects of CTL and TH epitopes
were tested using two-way ANOVAs.
High-Throughput Dataset Analysis
We used data from a study in which 396 synthetic peptides were
tested for immunogenicity in a HIV-1 subtype C cohort from South
Africa [18]. The dataset is freely available at www.hiv.lanl.gov/
content/immunology/hlatem/study3/index.html. We restricted
the analysis to 113 individuals for which the full-length genome of
the infecting virus was available. Of the total 44,748 assays
considered (113 patients6396 peptides), the peptide matched
exactly the amino acid sequence of the virus only in 13,127 cases
(29.3%). The straightforward correction for epitope detection bias
would be to restrict the analysis to this subset. However, 118 of the
total 179 positive T-cell reactions (65.9%) corresponded to
nonmatching peptides. These positives may be due to cross-
reactivity, but given that IFN responses can persist for years [107],
they could also correspond to cases of immune escape. Therefore, to
avoid missing a significant fraction of immune-driven viral
variability, we also included these nonmatching T-cell-positive
peptides as valid assays. If any, this should produce an artificially
positive association between variability and immunogenicity. We
then classified peptides in two categories according to whether or
not they produced at least one positive T-cell reaction and tested for
differences between these two groups using a one-way ANOVA in
which the number of valid assays per peptide was included as a
covariate in the model. Amino acid entropy values for each group
correspond to marginal means estimated from the ANOVA model.
Immune Activation Model
We developed a system of ordinary differential equations
describing how TH cell, CTL pAPC counts, and viral loads vary
with time as described in the text and Figure 3A. We also build a
control model including a nonimmune viral target cell type C
(Figure 3B). The full list of variables and parameters, a detailed
description of the model, and the systems of ordinary differential
equations are available in Appendix S1. Simulations were
performed in Mathematica 8 (Wolfram Research). SBML files
describing the model have been deposited in the BioModels
Database (MODEL1302180001 for immune activation model and
MODEL1302180002 for control model)-
Supporting Information
Appendix S1 Model variables, parameters, and systems of
differential equations describing the dynamics of wild-type and
T-cell (TH/CTL) escape viruses for the HIV and control models.
(PDF)
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